Antibody Ingredients TRIZ Cases

Buffered bispecific antibody formulation maintains thermal stability and solubility while enabling safe IV infusion for solid tumor therapy.

IgG1 and IgG3 anti-CD19 antibodies overcome CD19 internalization by engaging Fc receptors to trigger ADCC, preserving other immune cells.

Monoclonal antibodies bind the Lys158-Asp171 domain of human heparanase, neutralizing enzymatic activity to resolve specificity issues in cancer treatment.

Humanized antibodies target ENO1 to inhibit plasminogen activation, resolving the trade-off between therapeutic effectiveness and target specificity.

Antibodies block ILT2-HLA-G1 interactions to overcome immune evasion and enhance PD-1/PD-L1 therapy efficacy.

An anti-PSMA antibody drug conjugate links Exatecan to target PSMA-expressing cells for selective cytotoxic action.

A parallel polyethylene glycol unit masks hydrophobicity in ligand-drug conjugates to improve circulation stability.

Specific antibody sequences bind OX40 to activate NF-kB signaling, addressing clinical trial safety risks in cancer immunotherapy.

Polypeptide constructs with modified VH and VL domains enhance thermal stability through targeted amino acid substitutions.

REGN5381 activates NPR1 to provide sustained hemodynamic control without hypotension side effects.

Anti-LGR4 antibodies bind LGR4 receptors to inhibit cancer stem cell growth without disrupting RSPO1 signaling.

Phage display selects high affinity anti-IL-4R antibodies to neutralize interleukin-4 activity and block interleukin-13 signaling.

Combines a PD-1 antagonist with a selective 4-1BB agonist to enhance cytolytic T lymphocyte responses.

Bispecific antibodies targeting CEACAM5 and CD47 induce macrophage phagocytosis while minimizing cytokine release syndrome associated with T-cell activation.

Engineered monoclonal antibodies target specific N-linked glycosylation sites on BTLA to improve treatment safety and targeting selectivity.

Covalent conjugation of anti-influenza small molecules to Fc domains extends drug half-life through FcRn-mediated recycling.

Biodegradable polymeric implants deliver sustained therapeutic agents to local cancer sites, reducing systemic toxicity while inhibiting tumor growth.

A P4E11 monoclonal antibody binds a specific JMJD6 epitope to block collagen interaction.

Engineered anti-CD36 antibodies block fatty acid uptake to reduce metastatic tumor burden where conventional treatments lack receptor specificity.

Inhibiting USP7 in fibroblasts reduces VEGF secretion and angiogenesis, bypassing resistance mechanisms common in direct cancer cell treatments.

Segmenting the PD-1 binding interface via specific CDR regions reduces immune-related adverse events while maintaining high binding affinity.

Bispecific antibodies targeting CD40 and FAP confine immune activation to the tumor microenvironment, reducing systemic toxicity from cytokine release syndrome.

CBLB502 combined with anti-PD1 and anti-CTLA4 antibodies overcomes primary resistance in triple negative breast cancer models.